Adaptive Biotechnologies and Collaborators to Highlight New immunoSEQ Data at AACR 2019

SEATTLE–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AACR19?src=hash" target="_blank"gt;#AACR19lt;/agt;–Adaptive Biotechnologies and its collaborators will present 11 studies,
including an oral presentation and 10 poster presentations, at the
American Association of Cancer Research (AACR) Annual Meeting in
Atlanta, GA, March 29 – April 3.

New data will demonstrate how immunosequencing at scale and with
precision using Adaptive’s immunoSEQ^® Assay may be used in
clinical trials to predict overall survival and response to novel
immunotherapies, such as checkpoint inhibitors and cancer vaccines, in
solid tumors. Other data will examine the ability of immunoSEQ to
quantify and characterize the individual T cell receptors (TCR) of tumor
infiltrating lymphocytes (TILs), a type of white blood cell that attacks
cancer cells and controls tumor proliferation, to assist in identifying
subtypes of colorectal cancer. This information may be used to help
determine response to immunotherapy and patient outcomes among subtypes.
Collectively the studies also demonstrate a growing use of immunoSEQ by
academia and the pharmaceutical industry to help guide clinical research.

“Adaptive’s immune medicine platform is essential to helping our
academic and pharmaceutical industry partners decode the information
stored in our immune systems to answer translational research questions
and discover new prognostic and diagnostic signals in oncology clinical
trials,” said Chad Robins, CEO and co-founder of Adaptive
Biotechnologies. “Making this tool widely available to research partners
helps us drive toward our goal of transforming medicine to improve
patient lives.”

Abstracts are available on AACR website: https://www.abstractsonline.com/pp8/#!/6812.
immunoSEQ presentations of interest include:

• Exploratory analysis of T cell repertoire dynamics upon systemic
  treatment with the oncolytic virus pelareorep in combination with
  pembrolizumab and chemotherapy in patients with advanced pancreatic
  adenocarcinoma (abstract #2272/1), poster presentation, April 1,
  1:00 – 5:00 pm ET, Exhibit Hall B, Section 20
• Tumor infiltrating lymphocytes, immunoSEQ, and CMS classification
  in the molecular epidemiology of colorectal cancer study,
  (abstract #2332/1), poster presentation, April 1, 1:00 – 5:00 pm ET,
  Exhibit Hall B, Section 23
• Detection of tumor T-cell clones in mediastinal lymph nodes is
  associated with lower risk of tumor progression (abstract
  #3175/28), poster presentation, April 2, 8:00 am – 12:00 pm ET,
  Exhibit Hall B, Section 21
• Spatially resolved immunogenomic analyses reveal diverse sub
  tumoral microenvironments in the context of melanoma immunotherapy
  (abstract #3776/9), April 2, 1:00 – 5:00 pm ET, Exhibit Hall B,
  Section 7

About immunoSEQ Assays

Adaptive’s immunoSEQ Assay helps researchers make discoveries in areas
such as oncology, autoimmune disorders, infectious diseases and basic
immunology. The immunoSEQ Assay can identify millions of T- and B-cell
receptors from a single sample in exquisite detail. Offered as a Service
or Kit, the immunoSEQ Assay is used to ask and answer translational
research questions and discover new prognostic and diagnostic signals in
clinical trials. immunoSEQ Assay provides quantitative, reproducible
sequencing results along with access to powerful, easy-to-use analysis
tools. The immunoSEQ Assay is for research use only and is not for use
in diagnostic procedures.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a pioneer and leader in immune-driven
medicine that aims to improve people’s lives by learning from the wisdom
of their adaptive immune systems. Adaptive’s proprietary immune medicine
platform reveals and translates insights from our adaptive immune
systems with unprecedented scale and precision. Working with drug
developers, clinicians and academic researchers, we are applying these
insights to develop products that will transform the way diseases such
as cancer, autoimmune conditions, and infectious diseases are diagnosed
and treated. For more information, please visit adaptivebiotech.com.

Contacts

Adaptive Biotechnologies
Beth Keshishian (media)
917-912-7195
[email protected]